Cargando…

Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes

AIM: To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post-meal inflammatory and glycative biomarkers in patients with Type 2 diabetes. METHODS: This test-meal sub-study in the USA is from a previously reported clinical trial comparing the effect on glyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Beisswenger, P J, Brown, W V, Ceriello, A, Le, N A, Goldberg, R B, Cooke, J P, Robbins, D C, Sarwat, S, Yuan, H, Jones, C A, Tan, M H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178784/
https://www.ncbi.nlm.nih.gov/pubmed/21517955
http://dx.doi.org/10.1111/j.1464-5491.2011.03324.x
_version_ 1782212436663730176
author Beisswenger, P J
Brown, W V
Ceriello, A
Le, N A
Goldberg, R B
Cooke, J P
Robbins, D C
Sarwat, S
Yuan, H
Jones, C A
Tan, M H
author_facet Beisswenger, P J
Brown, W V
Ceriello, A
Le, N A
Goldberg, R B
Cooke, J P
Robbins, D C
Sarwat, S
Yuan, H
Jones, C A
Tan, M H
author_sort Beisswenger, P J
collection PubMed
description AIM: To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post-meal inflammatory and glycative biomarkers in patients with Type 2 diabetes. METHODS: This test-meal sub-study in the USA is from a previously reported clinical trial comparing the effect on glycaemic control of 24 weeks of thrice-daily pre-meal insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension) or bedtime insulin glargine, both plus metformin. In the sub-study, glucose, insulin, triglycerides, high-sensitivity C-reactive protein, tumour necrosis factor α, interleukin-6, methylglyoxal and 3-deoxyglucosone were measured during the post-meal period of a mixed-meal breakfast at the final visit. Prandial + basal (n = 25) and basal (n = 21) insulin were administered at the same times as during the previous 24 weeks. RESULTS: Post-meal, the prandial + basal insulin group had significantly higher insulin, lower glucose and triglycerides, as well as lower high-sensitivity C-reactive protein, tumour necrosis factor α and interleukin-6, than the basal insulin group. Glucose incremental area under the concentration curve significantly correlated with high-sensitivity C-reactive protein, tumour necrosis factor α, interleukin-6, methylglyoxal and 3-deoxyglucosone incremental area under the concentration curve. Insulin incremental area under the concentration curve correlated inversely with high-sensitivity C-reactive protein and tumour necrosis factor α incremental area under the concentration curve. However, after adjusting for glucose incremental area under the concentration curve, these inverse correlations were no longer significant. Triglyceride incremental area under the concentration curve was not correlated with any biomarker incremental area under the concentration curve. CONCLUSIONS: Controlling post-meal hyperglycaemia with prandial + basal insulin in patients with Type 2 diabetes attenuates meal-induced increases in high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor α compared with basal insulin. The rise in post-meal glucose, but not triglycerides, significantly correlated with the rise in post-meal inflammatory and glycative biomarkers.
format Online
Article
Text
id pubmed-3178784
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-31787842011-09-28 Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes Beisswenger, P J Brown, W V Ceriello, A Le, N A Goldberg, R B Cooke, J P Robbins, D C Sarwat, S Yuan, H Jones, C A Tan, M H Diabet Med Original Articles AIM: To determine if a regimen with prandial + basal insulin compared with basal insulin attenuates post-meal inflammatory and glycative biomarkers in patients with Type 2 diabetes. METHODS: This test-meal sub-study in the USA is from a previously reported clinical trial comparing the effect on glycaemic control of 24 weeks of thrice-daily pre-meal insulin lispro mix 50 (50% insulin lispro, 50% insulin lispro protamine suspension) or bedtime insulin glargine, both plus metformin. In the sub-study, glucose, insulin, triglycerides, high-sensitivity C-reactive protein, tumour necrosis factor α, interleukin-6, methylglyoxal and 3-deoxyglucosone were measured during the post-meal period of a mixed-meal breakfast at the final visit. Prandial + basal (n = 25) and basal (n = 21) insulin were administered at the same times as during the previous 24 weeks. RESULTS: Post-meal, the prandial + basal insulin group had significantly higher insulin, lower glucose and triglycerides, as well as lower high-sensitivity C-reactive protein, tumour necrosis factor α and interleukin-6, than the basal insulin group. Glucose incremental area under the concentration curve significantly correlated with high-sensitivity C-reactive protein, tumour necrosis factor α, interleukin-6, methylglyoxal and 3-deoxyglucosone incremental area under the concentration curve. Insulin incremental area under the concentration curve correlated inversely with high-sensitivity C-reactive protein and tumour necrosis factor α incremental area under the concentration curve. However, after adjusting for glucose incremental area under the concentration curve, these inverse correlations were no longer significant. Triglyceride incremental area under the concentration curve was not correlated with any biomarker incremental area under the concentration curve. CONCLUSIONS: Controlling post-meal hyperglycaemia with prandial + basal insulin in patients with Type 2 diabetes attenuates meal-induced increases in high-sensitivity C-reactive protein, interleukin-6 and tumour necrosis factor α compared with basal insulin. The rise in post-meal glucose, but not triglycerides, significantly correlated with the rise in post-meal inflammatory and glycative biomarkers. Blackwell Publishing Ltd 2011-09 /pmc/articles/PMC3178784/ /pubmed/21517955 http://dx.doi.org/10.1111/j.1464-5491.2011.03324.x Text en Journal compilation © 2011 Diabetes UK http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Articles
Beisswenger, P J
Brown, W V
Ceriello, A
Le, N A
Goldberg, R B
Cooke, J P
Robbins, D C
Sarwat, S
Yuan, H
Jones, C A
Tan, M H
Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
title Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
title_full Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
title_fullStr Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
title_full_unstemmed Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
title_short Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes
title_sort meal-induced increases in c-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with type 2 diabetes
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178784/
https://www.ncbi.nlm.nih.gov/pubmed/21517955
http://dx.doi.org/10.1111/j.1464-5491.2011.03324.x
work_keys_str_mv AT beisswengerpj mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT brownwv mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT cerielloa mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT lena mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT goldbergrb mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT cookejp mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT robbinsdc mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT sarwats mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT yuanh mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT jonesca mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT tanmh mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes
AT mealinducedincreasesincreactiveproteininterleukin6andtumournecrosisfactoraareattenuatedbyprandialbasalinsulininpatientswithtype2diabetes